In biochemical assays, motesanib potently inhibits the activity of both Kit (50% inhibitory concentration [IC50] = 8 nM) and PDGFR (IC50 = 84 nM) [9], suggesting that it may have direct antitumor activity in GIST [14,15]. This evidence concerns the gene PDGFRB and gastrointestinal stromal tumor.